Spero Therapeutics

Spero Therapeutics is a global, multi-asset, clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts. As a leader in the field of Gram-negative antibiotics, our mission is to address MDR infections by developing highly differentiated and transformative antibiotics through cutting-edge science to meet critical unmet needs. Spero Therapeutics is developing a range of novel product candidates with the potential to make a meaningful impact on patients and have significant commercial applications. As a leader in the infectious disease space, we are highly committed to developing new therapies for patients with severe infections.